Download PDF
Thromb Haemost 2001; 85(02): 371-372
DOI: 10.1055/s-0037-1615709
Letters to the Editor
Schattauer GmbH

Hemostatic Effects of Tamoxifen in Hereditary Hemorrhagic Telangiectasia

Leo R. Zacharski
1   Department of Veterans Affairs Medical Center, White River Jct., Vermont
,
Scott D. Dunbar
2   Department of Medicine, Dartmouth Medical School, Lebanon, NH
,
William A. Newsom Jr.
3   Sierra Nevada Cancer Center, Grass Valley, California, USA
› Author Affiliations
Further Information

Publication History

Received 12 September 2000

Accepted 13 September 2000

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Jacobson BS. Hereditary hemorrhagic telangiectasia: A model for blood vessel growth and enlargement. Am J Pathol 2000; 156: 737-42.
    CrossrefPubMedGoogle Scholar
  • 2 Lund VJ, Howard DJ. A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia. Am J Rhinol 1999; 13: 319-22.
    CrossrefPubMedGoogle Scholar
  • 3 Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25: 137-45.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Oberhoff C, Szymeczek J, Hoffmann O, Winkler UH, Kaiser S, Schindler AE. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat 1998; 50: 73-81.
    CrossrefPubMedGoogle Scholar
  • 5 Ounnoughene N, Molho P, Stieltjes N, Sultan Y. Effect of tamoxifen on von Willebrand factor levels. Arch Intern Med 1977; 157: 1613.
    PubMedGoogle Scholar
  • 6 Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156: 1806-10.
    CrossrefPubMedGoogle Scholar
  • 7 Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993; 4: 935-42.
    CrossrefPubMedGoogle Scholar
  • 8 Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Jpn J. Cancer Res 1993; 84: 455-61.
    CrossrefPubMedGoogle Scholar
  • 9 Fukutomi T, Adachi I, Watanabe T, Nanasawa T, Yamamoto H. Effects of combined tamoxifen and medroxyprogesterone treatment on coagulationfibrinolytic systems in patients with advanced breast cancer. Acta Oncol 1993; 32: 573-4.
    PubMedGoogle Scholar
  • 10 Jankowski J, Ramlau C, Kopczynski Z, Boryska M. The influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J. Gynaecol Oncol 1993; 14: 155-8.
    PubMedGoogle Scholar
  • 11 Caleffi M, Fentiman IS, Clark GM, Wang DY, Needham J, Clark K, La Ville A, Lewis B. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988; 119: 335-9.
    CrossrefPubMedGoogle Scholar
  • 12 Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer 1988; 61: 1316-9.
    CrossrefPubMedGoogle Scholar
  • 13 Sureda A, Cesar J, Garcia Frade LJ, Garcia Avello A, Fernandez Fuertes I, Navarro JL. Hereditary hemorrhagic telangiectasia: analysis of platelet aggregation and fibrinolytic system in seven patients. Acta Haematol 1991; 85: 119-23.
    CrossrefPubMedGoogle Scholar
  • 14 Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
    CrossrefPubMedGoogle Scholar
  • 15 Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI. Decision Analysis Of Tamoxifen for the Prevention of Invasive Breast Cancer. Cancer J 2000; 6: 169-178.
    PubMedGoogle Scholar
  • 16 Dunbar S.D., Ornstein D. L., Zacharski L.R.. Treatment of cancer with inhibitors of the plasminogen activator – plasmin system. Exp Opin Invest Drugs 2000; 9: 2085-92.
    CrossrefPubMedGoogle Scholar
  • 17 Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57: 3585-93.
    PubMedGoogle Scholar
  • 18 Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107 (Suppl. 04) 571-3.
    CrossrefPubMedGoogle Scholar
  • 19 Richtsmeier W, Weaver G, Streck W, Jacobson H, Dewell R, Olson J. Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1984; 92: 564-70.
    CrossrefPubMedGoogle Scholar
  • 20 Santibanez JF, Iglesias M, Frontelo P, Martinez J, Quintanilla M. Involvement of the Ras/MAPK Signaling Pathway in the Modulation of Urokinase Production and Cellular Invasiveness by Transforming Growth Factor-beta(1) in Transformed Keratinocytes. Biochem Biophys Res Commun 2000; 273: 521-7.
    CrossrefPubMedGoogle Scholar
  • 21 Park IK, Lyu MA, Yeo SJ, Han TH, Kook YH. Sp1 mediates constitutive and transforming growth factor beta-inducible expression of urokinase type plasminogen activator receptor gene in human monocyte-like U937 cells. Biochim Biophys Acta 2000; 1490 (Suppl. 03) 302-10.
    CrossrefPubMedGoogle Scholar
  • 22 Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bernabeu C. Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem 1998; 273: 33011-9.
    CrossrefPubMedGoogle Scholar
  • 23 Wileman SM, Booth NA, Moore N, Redmill B, Forrester JV, Knott RM. Regulation of plasminogen activation by TGF-beta in culutred human retinal endothelial cells. Br J Ophthalmol 2000; 84: 417-22.
    CrossrefPubMedGoogle Scholar
  • 24 Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genestein: emerging role for its effects via transforming growth factor beta signalling pathways. Am J Clin Nutr 1998; 68: 1418S-25S.
    CrossrefPubMedGoogle Scholar
  • 25 Takahashi H, Uno S, Watanabe Y, Arakawa K, Nakagawa S. Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin. Neuroreport 2000; 11 (Suppl. 05) 1111-5.
    CrossrefPubMedGoogle Scholar
  • 26 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29 (Suppl. 03) 236-61.
    CrossrefPubMedGoogle Scholar